The US Food and Drug Administration is moving slowly in drawing regulatory boundaries for CBD businesses. Members of Congress have called for clarity, but the FDA says it has no plans to give cannabis derivatives the green light ...
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets. Most content is available to subscribers only.